Torray Fund ABBV trades
Robert Torray
Torray Fund AbbVie Inc stake
total: 73
Trades details
- Total transactions:
- 3
- New positions:
- 1
- Added:
- 1
- Reduced:
- 1
- Held since:
- 2025 Q2
- Held for:
- 6 quarters
- Latest activity:
- 2026 Q3
According to 2026 Q3 report, Torray Fund holds 60,000 AbbVie Inc (ABBV) shares with a market value of roughly $15.39M accounting for 4.04% of the overall portfolio. To date, the estimated cost basis is nearly $188.37 for "buy" trades and estimated average "sell" price is $256.42. Torray Fund first purchased ABBV in 2025 Q2, initially acquiring 69,640 shares. Since the initial investment in AbbVie Inc (ABBV), Torray Fund has made 2 more transactions.
When did Torray Fund buy AbbVie Inc (ABBV)?
Torray Fund first invested in AbbVie Inc (ABBV) in 2025 Q2 at the reported quarter-end price of $186.11 per share.
What's the cost basis of Torray Fund's ABBV stake?
The estimated cost basis for AbbVie Inc (ABBV) stake is around $188.37 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $188.37
- Weighted AVG sell price:
- $256.42
Torray Fund's historical trades in AbbVie Inc
3 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q3
|
4.04%
|
60,000
|
$256.42
|
$15,385,200
|
-20.00% (-15,000)
|
-1.08%
|
|
2026 Q2
|
4.60%
|
75,000
|
$217.72
|
$16,329,000
|
+7.70% (+5,360)
|
+0.33%
|
|
2025 Q2
|
3.91%
|
69,640
|
$186.11
|
$12,960,700
|
new
|
+3.91%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.